Overview

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
Recent NewsMore >>
DateTitle 
01/23/17Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer, infectious diseases, and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has authorized the company’s Investigational New Drug Application (IND) for its ... 
Printer Friendly Version
12/19/16NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 19, 2016-- NantKwest (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases today announced that the company will be hosting an Investor/Analyst Day on January 8th in San Francisco. NantKwest will be sharing with ... 
Printer Friendly Version
12/12/16NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases, announced that the company presented results from a preclinical study on the company’s high affinity Natural Killer (haNK) cell therapy program at the S... 
Printer Friendly Version
11/28/16NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--Nov. 28, 2016-- NantKwest Inc. (Nasdaq:NK) today announced that Company management will present at the Piper Jaffray 28th Annual Health Care Conference in New York, NY at 4:00 pm Eastern Time (ET) on Tuesday, November 29, 2016. NantKwest’s presentation will include a business overview and clinical update. Details are below: Piper Jaffray 28th Annual Healthcar... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Past EventsMore >>
DateTitle
01/08/17 5:00 p.m. PT
Investor/Analyst Day
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.